Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

Speciality: Oncology


Speaker:

Dr Peush Bajpai | MBBS, MD - Medicine, DM - Medical Oncology,

Dr. Ankur Nandan Varshney | Consultant Medical Oncology, Fortis Memorial Research Institute (FMRI)

Description:

A warm welcome to all the medical professionals in this insightful session on Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC.

Managing ALK-positive Non-Small Cell Lung Cancer (NSCLC) presents unique challenges, especially when the disease metastasizes to the central nervous system (CNS). The brain-blood barrier often limits the efficacy of many systemic therapies, making CNS metastases a significant hurdle in treatment. Dr. Peush Bajpai and Dr. Ankur Nandan Varshney will delve into the complexities of this challenge, highlighting how newer generation ALK inhibitors are specifically designed to penetrate the CNS more effectively, offering better control of brain metastases and improving patient outcomes. This session will explore the latest strategies and best practices for addressing CNS involvement in ALK+ NSCLC.

Understanding the unique pharmacokinetic properties of CNS-penetrant ALK TKIs is crucial for optimizing patient management. This webinar will provide an in-depth look at current research, clinical trial data, and real-world experiences related to treating brain metastases in ALK+ NSCLC. Don't miss this opportunity to gain an overall knowledge on understanding the best practices in navigating the CNS challenge in ALK-positive NSCLC. Listen to the webinar, grab the shared knowledge, and follow Hidoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

2.

Dostarlimab Boosts Long-Term Survival in Endometrial Cancer

3.

Germline Profiling May Improve Risk Stratification in t-MNs

4.

Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.

5.

Scientists call into question safety of potential new anticancer treatment


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot